28.72
0.01 (0.03%)
| Penutupan Terdahulu | 28.71 |
| Jumlah Dagangan | 29,732 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.37 |
| Harga / Jualan (P/S) | 56.77 |
| Harga / Buku (P/B) | 25.19 |
| Julat 52 Minggu |
| Margin Keuntungan | -121.73% |
| Margin Operasi (TTM) | -94.48% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 170.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.68% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -75.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.20 M |
| Pulangan Atas Aset (ROA TTM) | -13.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zymeworks Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| Purata | -0.06 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 102.76% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |